PALB2 germline pathogenic in metastatic PDAC: behaves BRCA-like; case series support plat...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PALB2-GERMLINE-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | PALB2 germline pathogenic |
| Disease | DIS-PDAC |
| ESCAT tier | IIA |
| Recommended combinations | FOLFIRINOX (platinum induction), olaparib maintenance (off-label per NCCN) |
| Evidence summary | PALB2 germline pathogenic in metastatic PDAC: behaves BRCA-like; case series support platinum sensitivity and PARPi activity. POLO germline-only and BRCA- restricted; NCCN allows off-label olaparib for HRR-mutated. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing mandatory. CAPS surveillance protocol for first-degree relatives.
Used By
No reverse references found in the YAML corpus.